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Abstract
MicroRNAs (miRNAs) are short non-coding RNAs that are involved in several important biological processes
through regulation of genes post-transcriptionally. Carcinogenesis is one of the key biological processes where
miRNAs play important role in the regulation of genes. The miRNAs elicit their effects by binding to the 3’
untranslated region (3’UTR) of their target mRNAs, leading to the inhibition of translation or the degradation of the
mRNA, depending on the degree of complementary base pairing. To-date more than 1,000 miRNAs are postulated
to exist, although the field is moving rapidly. Currently, miRNAs are becoming the center of interest in a number of
research areas, particularly in oncology, as documented by exponential growth in publications in the last decade.
These studies have shown that miRNAs are deregulated in a wide variety of human cancers. Thus, it is reasonable
to ask the question whether further understanding on the role of miRNAs could be useful for diagnosis, prognosis
and predicting therapeutic response for prostate cancer (PCa). Therefore, in this review article, we will discuss the
potential roles of different miRNAs in PCa in order to provide up-to-date information, which is expected to
stimulate further research in the field for realizing the benefit of miRNA-targeted therapeutic approach for the
treatment of metastatic castrate resistant prostate cancer (mCRPC) in the near future because there is no curative
treatment for mCRPC at the moment.
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Introduction
Prostate cancer (PCa) is considered to be the most diag-
nosed cancer [1] and the second leading cause of cancer
death in men older than 40 years of age in the USA [2].
The major problem of PCa is the development and
acquisition of castrate resistant prostate cancer (CRPC)
phenotype which eventually leads to the development of
skeletal metastasis (mCRPC), at which point it becomes
an incurable disease [1]. Therefore, investigations are
underway to find the molecular basis of mCRPC so that
novel therapeutic strategies could be devised. To that
end many novel molecules are being tested and interro-
gated, among which microRNAs (miRNAs) are becom-
ing an attractive area of research.
The miRNAs are small, noncoding subset of RNAs
which consist of about 18-22 nucleotides and bind to
the 3’ untranslated region of messenger RNAs (mRNAs)
[3]. By this action, they cause post-transcriptional inhibi-
tion or degradation of target mRNA, depending on the
degree of complementary base pairing [4-6]. The miR-
NAs were first discovered in 1993 while studying Cae-
norhabditis elegans [7]. The first miRNA discovered was
lin-4. It is a small, non-coding RNA molecule that was
found to play a role in the development through a nega-
tive effect on lin-14 expression [7-9]. Seven years later,
in 2000, let-7, the second miRNA was discovered, again
in the C. elegans [9,10]. During the past 12 years, signifi-
cant advances have been made in miRNA research lead-
ing to the discovery of over 4,500 miRNAs in
vertebrates, flies, worms, plants, and viruses [9,11,12]
out of which more than 1,000 miRNAs have been fully
characterized and the number is expected to grow in
the coming years. The miRNAs are being implicated in
the regulation of an increasing number of physiological
processes. It is also believed now that they play an
important role in the regulation of many cellular func-
tions ranging from maintenance to differentiation and
tissue development, from metabolism to cell cycle
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aberrant expression of miRNAs will have impact on var-
ious biological processes where they are implicated,
which will result in a variety of pathological events such
as infection [13,17,18], cardiovascular diseases [19], neu-
rodegenerative diseases [20] and, most importantly, can-
cer [13].
The role of miRNAs in cellular growth, differentiation
and apoptosis of cancer cells through their interactions
with their target mRNA has been studied [21-23]. miR-
NAs may be oncogenic or tumor suppressors [23,24],
with oncogenic being up-regulated and the tumor sup-
pressors being down-regulated in cancers. Generally, the
importance of miRNAs in cancer is emphasized by the
fact that around 50% of all miRNA genes are positioned
in the so called ‘fragile sites’, the cancer associated geno-
mic regions which are repeatedly changed in cancer. A
lot of information has already been identified about
aberrant miRNAs expression in cancers; the understand-
ing of the functional importance of these aberrations has
not been molecularly exploited [25].
The role of miRNAs in PCa is becoming clearer by
understanding the interactions between miRNAs and
their targets and the resulting impact on carcinogenesis
of the prostate [23,26,27]. It is believed that several miR-
NAs and their targets are aberrantly expressed in PCa
which, in turn, alter the cellular growth, invasion, and
metastatic potential of prostate cancer cells. The abnor-
mal expressions of certain miRNAs are now considered
valuable biomarkers for diagnosis, prognosis and classifi-
cation of PCa [23,28,29]. All of the above information
underscores the importance of the biology of miRNAs
in PCa. Their specific abnormalities, and how one could
regulate their expressions will likely become novel ave-
nues by which newer therapeutic strategies could be
developed for the treatment of mCRPC.
miRNA biogenesis
The biogenesis of miRNA involves many critical steps;
the initial phase is the transcription by RNA polymerase
II that leads to the formation of primary miRNA (pri-
miRNA) which comprises of hundreds to thousands of
nucleotides [9,30]. The second phase is catalyzed by a
ribonuclease called ribonuclease III (RNase III), Drosha.
This step leads to the split of pri-miRNA and results in
what is called a precursor miRNA (pre-miRNA), which
usually comprises of around 70 nucleotides, and this
phase is accomplished with the help of dsRBD protein,
DGCR8, a protein that helps to ensure a perfect and
efficient processing of pri-miRNA into pre-miRNA
[9,31,32]. Thereafter, a nuclear export factor, called
exportin 5, binds to the pre-miRNA and transports it
into the cytoplasm where the next processing phase take
place [9,33,34]. Here another RNase III, dicer, interacts
with the pre-miRNA, and the outcome of this process is
the formation of a RNA duplex of around 22 nucleo-
tides, which is the mature miRNA consisting of double-
stranded duplex. Dicer usually operates with the help of
a different dsRBD protein, the trans-activator RNA
(tar)-binding protein (TRBP) [9,35,36]. Subsequently, all
these steps allow the mature miRNA cooperate with the
RNA-induced silencing complex (RISC) [9,37,38], and
ultimately allow miRNA to control post transcriptional
regulation of functional mRNAs.
miRNA and cancer stem cells in prostate cancer
Cancer stem cells (CSCs), also called tumor-initiating
cells, are a group of cells which play an important role
in the progression of cancer and its metastasis [39]. The
CSCs hypothesis assumes that cancers are basically
derived from a small fraction of cancer cells that have
exclusive ability to self-renew and initiate/maintain the
tumor [40,41]. This specific ability of CSCs allows to
initiate the development of cancer as documented first
in human leukemia [42,43]. For the isolation and identi-
fication of CSCs many markers have been used. Early
on, CD44 (an adhesion molecule) was used to identify
CSCs, individually or sometimes in combination with
other markers. It was shown that Prostate CSCs that
have increased clonogenic potential [44], and tumor
initiating ability and metastasis [45,46] capacities, have
increased CD44
+ cell population.
Emerging evidence suggests that miRNAs may func-
tion as the regulators of CSC characteristics, as docu-
mented by many studies [47-50]. Studies have clearly
shown that the expression levels of certain miRNAs in
stem cells are different from other normal tissues
[40,51], suggesting that miRNAs are important regulator
of CSC function. One example is miR-34a, a p53 target
[52-56], which has strong anti-tumor and anti-metastasis
effects [57]. Studies have shown that miR-34a is down
regulated in CD44
+ PCa cells, and its forced expression
in CD44
+ PCa cells resulted in the inhibition of clono-
genic growth and inhibition of metastatic behavior and
tumor regeneration [57]. The miR-34a was also estab-
lished as an important negative regulator of CD44
+ PCa
cells, and it is assumed that this decreased expression of
miR-34a in CD44
+ PCa cells (including CSCs) plays an
important role in PCa development and metastasis [57].
Moreover, the expression of miR-34a antagomirs in
CD44
- prostate cancer cells promoted tumor develop-
ment and metastasis [57].
Taking into consideration the prevalent expression of
CD44 in CSCs and the role of CD44 in mediating CSC
migration and homing, suggesting its role in metastasis
in various malignancies including PCa whereby the role
of miR-34a in controlling CSC characteristics appears to
be important, and thus targeting of miR-34a pathways
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[57]. Further studies are underway in order to establish
the molecular interplay between miRNAs and CSCs in
PCa and other human malignancies.
The role of miRNAs in the processes of Epithelial-to-
Mesenchymal Transition (EMT) in PCa
The process of EMT is defined as one when epithelial
cells acquire phenotypic characteristics of mesenchymal
cells whereby the epithelial cells change their epithelial
cobblestone phenotype to a mesenchymal elongated
fibroblastic phenotype, which contributes to increased
cell motility and invasion that is required for metastatic
process. During EMT, cancer cells lose epithelial cell-
cell junctions associated with a decrease in the expres-
sion of epithelial proteins such as E-cadherin and junc-
tion plakoglobin, and the increase in expression of
mesenchymal markers such as vimentin, fibronectin and
a-smooth muscle actin. These changes are also asso-
ciated with augmented activity of matrix metalloprotei-
nases (MMPs), such as MMP2, MMP3, MMP9, which
leads to an invasive phenotype [58]. All of the above
mentioned processes lead to increased invasion and
migration in many cancers including PCa [59]. Because
the miRNAs are part of the cellular signaling circuit
that controls EMT [60], it has been suggested that many
miRNAs families, including miR-200 family and miR-
205, play important roles in controlling EMT [61-63].
The miRNA 143 and miRNA 145 are other two miR-
N A st h a ta r ea s s u m e dt op l a yar o l ei nE M T .I nP C a ,
miR-143 and miR-145 are deregulated in primary cancer
compared with normal prostate tissue [64-67]. The up-
regulation of miR-143 in prostate cancer cells represses
mesenchymal markers (vimentin and fibronectin) and
increases the epithelial marker E-cadherin [1], while the
up-regulation of miR-145 leads to the same effects
except for vimentin [1]. The previous information shows
that miRs-143 and -145 may be suppressors of EMT,
and based on the fact that EMT plays an important role
in invasion and migration consistent with mesenchymal
characteristics allows detachment and movement of cells
from the primary tumor [68]. Therefore, it can be
assumed that miRs-143 and -145 inhibit invasion and
migration in prostate cancer.
The role of most miRNAs in regulating EMT is still
n o tac l e a r - c u tw i t hj u s tah a n d f u lo fm i R N A sb e i n g
evaluated for their role in EMT of PCa [1,69,70] (Table
1). With the crucial role of miRNAs in EMT, it is
expected that the regulation of EMT by miRNAs in PCa
will be the center of many cutting-edge research in the
upcoming years.
The relationship between circulating miRNAs and tumor
progression in prostate cancer
Circulating miRNAs have been suggested as encouraging
biomarkers for noninvasive diagnosis in many tumors
[71]. It has been proposed that miRNAs profiles in
tumor cells have a prognostic value for some cancer
patients, and a similar correlation with serum miRNAs
profiles should be a viable approach [71].
Brase et al. [71] found that miR-375 was the top marker
in a screening study (metastatic vs. localized prostate
cancer) and that its expression is higher in prostate can-
cer tissue compared to normal epithelium. They also
found that it was considerably related to lymph-node sta-
tus of the prostate cancer patients, but no significant dif-
ference was observed in the serum levels of patients with
gleason score 8 tumors and gleason score 7 tumors. So, it
seems that the circulating level of miR-375 is associated
mainly with systemic disease (lymph node involvement
and metastasis) rather than the grading of primary pros-
tate cancer [71]. However, the definite role of miR-375 in
prostate cancer is still not very clear.
The role of miR-141 and miR-200b (both belong to the
same family of miRNAs) were reported to be the two lar-
gely over regulated miRNAs in prostate epithelial cells in
comparison with prostate stromal cells [71]. But the circu-
lating levels of miR-141 were found to be much higher in
the serum of patients with high-risk tumors when com-
pared to intermediate-risk samples. Also, circulating levels
of miR-141 have been found to differentiate between
patients with metastatic PCa and healthy controls [71].
Based on these limited studies, one could conclude
that circulating miRNAs may offer good perspective as
noninvasive biomarkers for tumor progression, including
prostate cancer, but further research has to be done in
this field in order reach a better understanding of the
role of miRNAs in the serum or plasma [71].
The specific roles of certain microRNAs in prostate cancer
As mentioned above, miRNAs are known to play impor-
tant roles in the progression of different cancers,
Table 1 Regulation of EMT in PCa by miRNAs
miRNA Effect in PCA Reference
miR-200b Down-regulation of ZEB1, ZEB2 and Snail 2 Kong 2009 [69]
miR-200 family Reverses EMT and down-regulates Notch-1 and Lin28B Kong 2010 [70]
miR-143 and miR-145 Suppression of mesenchymal markers and up-regulation of epithelial marker Peng 2011 [1]
Let-7 family Expression of epithelial markers Kong 2010 [70]
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suppressors wherein their elevated levels are indicators
of good prognosis. On the contrary, other miRNAs are
promoters of carcinogenesis and their expression levels
are elevated in advanced stage of some cancers, which
clearly suggests that these miRNAs may offer attractive
targets for therapy. In this section, we will discuss the
roles of certain miRNAs in prostate cancer as summar-
ized in Table 2.
Tumor suppressor miRNAs
The role of miRNA-15a and miRNA-16
Both of these miRNAs work as tumor suppressors
mediated through deregulation of multiple oncogenes,
and these oncogenes include: BCL2, MCL1, CCND1,
and WNT3A [25]. The aforementioned oncogenes can
promote cell proliferation, survival and invasion [25].
The down regulation of these miRNAs has been
reported in many malignancies including: CLL, Pituitary
adenoma, and Prostate carcinoma [25]. The miR-15a
and miR-16 are both located at 13q14.3, and the dele-
tions at this location have been reported in many malig-
nancies including: CLL, MM, Mantle cell lymphoma,
and Prostate carcinoma [25]. In a recent study, the
expression of miR-15a, miR-16-1 in PCa samples
showed consistent down regulation of these genes in
around 80% of cancer samples compared with that of
normal samples [25]. Studies have also shown that miR-
15a, miR-16-1 are down regulated in pituitary adenomas
in comparison with normal pituitary, which basically
enhances the assumption that they work as tumor sup-
pressors and that their knock down by allelic loss may
contribute to tumorigenesis.
BCL2 is an oncoprotein that performs an important
role in the genetic program of the eukaryotic cells, it
prevents cell death and its over-expression was found to
be related to many cancers such as: leukemia, lym-
phoma, and carcinomas in general [25]. It was reported
that miR-15a, miR-16-1 sequences and BCL2 mRNA
sequences share a complementary homology, and thus
the previous information collectively suggests that miR-
15a, miR-16-1 could suppress BCL2 by post transcrip-
tional repression [25]. It has been reported that miR-
15a, miR-16-1 cluster targets not only BCL2 but also
CCD1 (encoding cyclin D1) and WNT3A mRNAs,
which promote many prostate carcinogenic features
including; survival, proliferation, and invasion [25]. The
in vivo knock down of miR-15a, miR-16-1 resulted in
hyperplasia associated with CCD1 and WNT3A up reg-
ulation, all of the above evidence suggest that loss of
miR-15a and miR-16-1 may be a significant pathogenic
event during the development of PCa [25].
The miR-15 and miR-16 are usually down-modulated
in the tumor sustaining stroma, an observation that can
be explained by the effect of cancer cells on the stroma
[72]. The miR-15 and miR-16 have a tumor suppressor
activity on both cancer cell level and at the stromal
microenvironment [72]. Lately, it was also proposed that
miR-15 and miR-16 direct the expression of VEGF and
IL-6, two factors that stimulate tumor angiogenesis and
bone metastasis, respectively. Moreover, it was shown
that re-expression of miR-15 and miR-16 in cancer-
associated fibroblasts (CAFs) will cause attenuation of
the stromal support capability, and this will result in the
decrease in cell proliferation and migration in primary
and metastatic tumors [72]. These observations lead us
Table 2 miRNAs that influence PCa progression
miRNA Role in PCa Function Study
miR-15a and
miR-16
Tumor
suppressors
Inhibit cell proliferation, invasion and angiogenesis through regulation of
multiple targets
Aqeilan 2010 [25], Musumeci 2011[72]
miR-21 Onco-miRNA Increases tumor growth, invasion and metastasis Si 2007 [79], Selciklu 2009 [80], Li 2009
[81], Ribas 2009 [82]
miR-125b Onco-miRNA Increases cell proliferation and inhibits apoptosis Lee 2005 [84], Shi 2007 [26], Vere
White 2009 [85]
miR-143 Tumor
suppressor
Inhibits cell proliferation and migration by regulating KRAS, MAPK pathways
and cell cycle. Also inhibits metastasis
Clape 2009 [67], Xu 2011 [4], Friedman
2009 [73]
miR-145 Tumor
suppressor
Inhibits migration, invasion and metastasis Friedman 2009 [73]
miR-200 s Tumor
suppressor
Inhibit cell migration and invasion by reversing EMT Kong 2009 and 2010 [69,70]
miR-221 Onco-miRNA Stimulates cell growth and influences cell cycle progression Zheng 2011 [78], Galardi 2007 [77],
Sun 2009 [76], Pang 2010 [23].
miR-222 Onco-miRNA Increased cell cycle progression Galardi 2007 [77], Sun 2009 [76], Pang
2010 [23].
miR-488 Tumor
suppressor
Inhibits Androgen Receptor-mediated cell growth Sikand 2010 [75]
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15 and miR-16 are tumor suppressors, at least, on two
levels such as at the levels of tumor cell and stromal
cells.
The role of miR-143 and miR-145
We have discussed above the role of miR-143 in EMT.
Studies have shown that miR-143 is considerably
decreased in PCa, and its expression is further decreased
during cancer progression [67]. K-RAS (V-Ki-ras2
Kirsten rat sarcoma), a key molecule of EGFR/RAS/
mitogen-activated protein kinase (MAPK) signaling
pathway, is a viral oncogene homolog that was incrimi-
nated in cell proliferation and migration in response to
growth factors. The MAPK pathway also works at
another level through its effect on Androgen receptors
(AR), where it increases AR in response to low andro-
gen, and this is considered a main process in Androgen
derivation therapy relapse. K-RAS is a potential target of
miR-143 [73], thereby lower levels of miR-143 in pros-
tate cancer cells may be incriminated in carcinogenesis
due to the lack of its inhibitory effect on K-RAS and
MAPK pathway.
Xu et al. [4] showed that miR-143 regulates K-RAS, p-
ERK1/2, and cyclin D1 and plays a role in cell prolifera-
tion, migration, and chemosensitivity in prostate cancer.
They also showed that miR-143 over-expression in pros-
tate cancer cells represses proliferation and migration,
thereby augmenting sensitivity to docetaxel by affecting
EGFR/RAS/MAPK pathway. The expressions of miR-
NAs-143 and -145 (another miRNA which is assumed
to be tumor suppressor) were found to be down-regu-
lated considerably in metastasis samples [73]. Exploring
the correlation of the levels of miRNAs-143 and -145
with clinico-pathological features of PCa showed that
down-regulation of miRNAs-143 and -145 were nega-
tively associated with bone metastasis, the gleason score
and the levels of free PSA in primary PCa patients [73].
Over-expression of miR-143 and -145 by retrovirus
transfection decreased the ability of migration and inva-
sion in vitro, and tumor development and bone invasion
in vivo of PC-3 cells (a human PCa cell line originated
from a bone metastatic PCa specimen) [73]. Their up-
regulation also enhanced E-cadherin expression and
decreased fibronectin expression in PC-3 cells with fea-
tures of a less invasive morphologic pattern [73].
The information above suggests that miRs-143 and
-145 are related to bone metastasis of PCa and may play
a biological role in this process [73]. One could postu-
late that the possibility of using them in the clinical set-
ting as biomarkers to individualize different stages of
human PCa and could predict the development of bone
metastasis in patients well ahead of time [73]. Even
though up-regulation of miRNAs-143 and -145 are
found to suppress the aggressiveness and EMT of PC-3
cells with regard to bone metastasis, it did not have the
same effects on LNCaP cells that was derived from
lymph node metastasis [73]. Actually, deregulation of
miRs-143 and -145 was not found in lymph node metas-
t a s i si nc o m p a r i s o nt op r i m a r yP C as p e c i m e n s .T h i s
information suggests that miR-143 and -145 may have a
cell type-specific activity and could suppress only bone
metastasis without inhibiting lymph node metastasis,
and that the loss of these miRNAs could selectively pro-
mote metastasis, which could be due to deregulated
expression of other miRNAs such as miR-221 [73].
The role of miRNA-200
Studies from our laboratory have shown that the miR-
200 family controls epithelial-mesenchymal transition
(EMT) by targeting zinc-finger E-box binding homebox
1 (ZEB1) and ZEB2 [63,69,74]. There is enough evidence
to suggest that the processes of EMT can be elicited by
various growth factors, such as transforming growth fac-
tor b and platelet-derived growth factor-D (PDGF-D),
which is expressed in PCa tissue [69], and it was shown
that over-expression of PDGF-D in PC3 cells (prostate
cancer cell lines with high metastatic potential) leads to
the acquisition of the EMT phenotype [69]. It was also
proved that significant down-regulation of the miR-200
family in PC3 PDGF-D cells and in PC3 cells exposed
to purified active PDGF-D protein, resulting in the up-
regulation of ZEB1, ZEB2, and Snail2 expression (a tran-
scription factor which belongs to the snail protein family
and plays critical roles in the formation of tissues during
embryonic development) [69]. Interestingly, re-expres-
sion of miR-200b in PC3 PDGF-D cells led to reversal
of the EMT phenotype accompanied with the down-reg-
ulation of ZEB1, ZEB2, and Snail2 expression, and all of
these events were associated with greater expression
levels of epithelial markers [69]. Moreover, it was proved
that transfection of PC3 PDGF-D cells with miR-200b
considerably decreased the expression of ZEB1, ZEB2,
and Snail2 at both the mRNA and protein levels, with
simultaneous greater expression levels of epithelial mar-
kers such as E-cadherin, stratifin, CRB3, EpCAM, F11R,
and connexin 26, all of these events collectively led to
the inhibition of cell migration and invasion [69]. In a
breast cancer model, our studies have shown that in
vivo manipulation of miR-200b leads to significantly
reduced pulmonary metastases of breast cancer cells
[74] which further supports the role of miR-200 family
in metastases of human cancers.
It is well known that NF-B plays an essential role in
facilitating the processes of EMT induced by different
factors through up-regulation of ZEB1 and ZEB2, which
in turn suppress the expression of miR-200 family mem-
bers by binding to the E-box sequence of the miR-200
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expression of ZEB1 and ZEB2 by interacting with the 3’-
UTR of ZEB1 and ZEB2 mRNA [69]. All of these find-
ings suggest a double-negative feedback loop between
miR-200 and ZEB1/ZEB2 that permits the preservation
of the EMT phenotype, even after withdrawal of the
initial inducing signal, which might become a critical
target for the reversal of EMT [63]. From these facts, we
can conclude that PDGF-D-stimulated attainment of the
EMT phenotype in PC3 cells is, partly, an outcome of
suppression of miR-200 and that new strategies in
which miR-200 would be up-regulated will become an
auspicious approach for the treatment of invasive pros-
tate cancer [69].
The importance of miRNA-488
Another miRNA that has been associated with PCa is
miR-488. The miR-488 is encoded through AsTN1
gene. Two mature molecules results from the processing
of its precursors: miR-488* and miR-488 and both of
them are expressed predominantly in human brain tis-
sue [75]. Studies have shown that miR-488* was not
expressed in several prostate cancer cell lines, although
the etiology is still unclear and thus it is currently being
further investigated [75].
Androgen receptor is a direct target of miR-488, as
miR-488 has a binding site at the 3’UTR of AR gene
where it binds and suppresses its expression [75]. It was
shown that cells transfected with miR-488 results in
reduced expression of AR in both Androgen-dependent
(LNCaP) and Androgen-independent (C4-2B) PCa cells.
In both the cell lines, treatment with miR-488 mimics
was found to retard the growth of these cells, but this
was not the fact with AR-negative DU145 cells [75],
suggesting the regulatory role of miR-488 on AR expres-
sion. These results suggest that miR-488 could function
as a tumor growth suppressor, which is mediated by
deregulation of AR expression [75].
Although it is still too premature to make conclusions,
the results of these studies clearly showed that miR-488*
transfection into LNCaP and C4-2B cells led to the
repression of AR expression, thereby suggesting that
finding a way to increase the levels of endogenous miR-
488* could have a great impact on designing novel treat-
ment strategies for PCa.
Tumor promoter oncomiRNAs
The miRNA expression profiling analyses have shown
that many miRNAs are up-regulated in prostate cancer
[23]. These oncogenic miRNAs suppresses the apopto-
sis-related genes, so their over-expression leads to
increased tumor growth and metastasis [23].
The role of miRNA -221 and miRNA-222
The miR-221 and miR-222 are both considered as onco-
genic and were found to be associated with the develop-
ment and metastasis of prostate cancer [23]. One of the
methods through which these miRNAs elicit their effect
is by binding to one of their target mRNA, p27kip1 and
cause suppression, which results in tumor growth
[76,77]. Another action for them is their role in the
development or maintenance of castration-resistant
prostate cancer (CRPC), phenotype through a mechan-
ism that is not yet clearly understood, although it may
be through influencing response of AR-mediated signal-
ing in prostate cancer cells [76].
With regards to miR-221, studies have shown that
miR-221 levels are up-regulated in both ADPC and
AIPC compared to normal control [78]. One pathologic
process that plays an important role in the carcinogen-
esis and hormone therapy failure in PCa is neuroendo-
crine differentiation (NE), a process that is associated
with tumor progression and poor prognosis. Studies
have shown that miR-221 is capable of inducing NE dif-
ferentiation in LNCaP cells in an androgen deprived
environment, which may lead to Androgen Indepen-
dence (AI) [78]. It was revealed that miR-221 stimulates
the growth of LNCaP and LNCaP-AI cells, and it is con-
sistent with findings that the ectopic introduction of
miR-221 in low expressing LNCaP cells bolstered their
growth potential by inducing a G1-S shift in cell cycle
[78].
One paradox to mention about miR-221 is that
although the expression of miR-221 is higher in LNCaP-
AI cells (which are more invasive) compared to LNCaP
(which are less invasive), suggesting that miR-221 pro-
motes invasion of PCa cells [78] whereas the up-regula-
tion of miR-221 in LNCaP cells did not increase its
ability of increased cell migration, while the invasion
capacity of LNCaP-AI cells was deregulated by knock-
down of miR-221 expression. The aforementioned facts
can be explained by assuming that other pathways are
involved in regulating the migration capability of cells
during the progression of ADPC into AIPC. It was
further concluded that miR-221 could influence PCa via
regulation of DVL2 (Dishevelled 2), which in summary
is an important intracellular mediator of the WNT sig-
naling pathway. An important target gene for WNT is
MMP-7 (a member of cellular adhesion molecules
which controls cellular adhesion, invasion, and migra-
tion), and the activation of MMP-7 was found to greatly
strengthen the capability to destroy extracellular matrix,
especially in cancer cells [78], suggesting that miR-221
may play important role in the regulation of invasion
and metastasis.
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Another onco-miRNA is miR-21; it is usually up-regu-
lated in prostate cancer and plays a role in tumor
growth, invasion, and metastasis [79,80]. Lately, miR-21
was individualized as an oncogene which is up-regulated
in various cancers (glioma, breast cancer, colorectal can-
cer, stomach/gastric cancer, hepatocellular carcinoma,
pancreas cancer, lung cancer, cholangiocarcinoma, leu-
kemic cancer, and prostate cancer etc.) [81]. Anti-sense
studies of miRNA-21 in glioblastoma cell lines revealed
that it directs cell growth by inhibiting apoptosis while
it does not influence cell proliferation [81]. Recent stu-
dies have revealed an increase in apoptosis in DU145
and PC-3 cells after blocking miR-21 function, while
LNCaP cells, which have low level of miR-21, showed
no changes in apoptosis in response to miR-21 blockade
[81]. The information mentioned above insinuated that
miR-21 plays an important role in the resistance to
apoptosis observed in DU145 and PC-3 cells [81]. These
results also suggest that miR-21 might have a role to
play in AR-negative cells but this needs to be further
investigated.
Many genes have been identified as targets of miR-21
in carcinogenesis including; TPM1, PDCD4, and
MARCKS [81]. It has been shown that MARCKS (a
gene which encodes myristoylated alanine-rich C-kinase
substrate) has high frequency frameshift mutations dur-
ing carcinogenesis in hereditary nonpolyposis colorectal
cancer (HNCC) [81]. It was also revealed that the
expression of MARCKS is down-regulated in HCC tis-
sues in comparison with cirrhotic, benign liver tissues
[81]. MARCKS plays a part in TPA-mediated cellular
migration in neuroblastoma, probably through its effect
as a downstream target of Protein kinase C epsilon [81].
All these results suggest that MARCKS plays a role in
tumorigenesis, and the effect of miR-21 on PCa cell
motility and invasion may in part be due to its regula-
tion of MARCKS gene. Recent studies have also shown
that in the presence of androgen, AR can bind to
miPPR-21, a miR-21 promoter, and this results in the
over-expression of miR-21 at its transcription level, lead-
ing to castration resistance [82]. In support of what has
been mentioned above, anti-miR-21 may augment the
sensitivity of prostate cancer cells to apoptosis [81], and
also negatively affect the motility and invasive character-
istic of cancer cells [81].
In summary, it appears that miR-21 plays an essential
role in apoptosis and metastasis of PCa [81]. Since no
effective therapy is available to cure PCa, in part due to
the resistance of androgen-independent advanced pros-
tate cancer cells to apoptotic death, gene therapy that
targets miR-21 may be a potential alternative therapy
for androgen-independent PCa that have an up-regu-
lated expression of miR-21. Moreover, it is tempting to
speculate that natural agents (nutraceuticals) could serve
as a therapeutic strategy for PCa because many of these
agents could inhibit the expression of miR-21 as sug-
gested by our recent results in pancreas cancer [83].
The role of miRNA-125b
Another onco-miRNA is miR-125b which is considered
very important for cell proliferation [84] and it is over-
expressed in prostate cancer [23]. It has been reported
that the reduction of miRNA-125b was found to be
associated with the regulation of cellular proliferation of
cancer cells, and this effect was attenuated by co-trans-
fection of mature miRNA [84]. The biological role of
miR-125b in PC-3 cells was studied and it was revealed
that the depletion of miR-125b by numerous transfec-
tions of si-125b2 was followed by a substantial prolifera-
tion defect in PC-3 cells [84]. This growth defect was
not associated with aberrant accumulation of cells in
one stage of cell cycle or by apoptosis. Also, the deple-
tion of miR-125b by 2’-O-methyl oligonucleotide
showed the same phenotype with a similar effect on cell
proliferation [84].
Studies have also shown that transfection of mature
synthetic miR-125b causes PCa cell growth [84,85] and
this was in part due to its effect on the 3’UTR of BAK1
(a pro-apoptotic member of the BCL-2 gene family that
is involved in initiating apoptosis) transcript [26]. None-
theless, down-regulation of BAK-1 only could not
attenuate miR-125b’s growth stimulatory effect, suggest-
ing that there are other targets for miR-125b in prostate
cancer cells [26,85]. Some recent reports individualized
EIF4EBP1 (Eukaryotic translation initiation factor 4E-
binding protein 1, a gene that encodes one member of a
family of translation repressors proteins) as another spe-
cific target for miR-125b in PCa [65], but it is still not
conclusive, suggesting that future in-depth investigation
is warranted.
Conclusions and perspectives
Research investigations focused on miRNAs have sug-
gested a strong prognostic and therapeutic importance
of miRNAs in PCa. Such studies have established an
intimate relationship between prostate cancer and
miRNA with emerging data clearly suggesting that
miRNA is a very promising field although further in-
depth mechanistic studies are required to ascertain the
role of specific miRNA(s) and relevant target(s) in the
development and progression of PCa especially the
emergence of metastatic castrate resistant prostate can-
cer. Once we gain additional scientific knowledge it
would be easier to focus on the development of strate-
gies for up-regulation and down-regulation of specific
miRNA as a novel and targeted therapeutic approach
for the treatment of PCa. For example, our own studies
Hassan et al. Journal of Hematology & Oncology 2012, 5:9
http://www.jhoonline.org/content/5/1/9
Page 7 of 10with miR-21 in pancreatic and colon cancer models
have shown that targeted regulation of this miRNA can
lead to effective anticancer therapy [83,86-90]. As dis-
cussed above, miR-21 has been implicated in PCa as
well and, therefore, our strategy may also work in PCa,
which requires in-depth mechanistic pre-clinical studies.
Together, we believe that identification of key miRNAs
and their targets that are intimately involved with the
development and progression of PCa and parallel devel-
opment of strategies for deregulation of miRNAs would
allow inhibition of tumor growth, invasion, angiogenesis
and metastasis in PCa, which is expected to be clinically
useful for the management of patients diagnosed with
PCa.
Author details
1Department of Pathology, Karmanos Cancer Institute, Wayne State
University School of Medicine, Detroit, MI, USA.
2Department of Oncology,
Karmanos Cancer Institute, Wayne State University School of Medicine,
Detroit, MI, USA.
Authors’ contributions
OH and AA surveyed the literature and drafted manuscript. SS participated
in the design of this article. FHS conceived of the study and participated in
its design, coordination and finalization of the manuscript. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 February 2012 Accepted: 14 March 2012
Published: 14 March 2012
References
1. Peng X, Guo W, Liu T, Wang X, Tu X, Xiong D, et al: Identification of miRs-
143 and -145 that is associated with bone metastasis of prostate cancer
and involved in the regulation of EMT. PLoS One 2011, 6:e20341.
2. Hao Y, Zhao Y, Zhao X, He C, Pang X, Wu TC, et al: Improvement of
prostate cancer detection by integrating the PSA test with miRNA
expression profiling. Cancer Invest 2011, 29:318-324.
3. Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, Orntoft T, et al: MicroRNA
profiles of prostate carcinoma detected by multiplatform microRNA
screening. Int J Cancer 2011, 130:611-621.
4. Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z, et al: miR-143 decreases
prostate cancer cells proliferation and migration and enhances their
sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem
2011, 350:207-213.
5. Vella MC, Choi EY, Lin SY, Reinert K, Slack FJ: The C. elegans microRNA let-
7 binds to imperfect let-7 complementary sites from the lin-41 3’UTR.
Genes Dev 2004, 18:132-137.
6. Doench JG, Sharp PA: Specificity of microRNA target selection in
translational repression. Genes Dev 2004, 18:504-511.
7. Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4
encodes small RNAs with antisense complementarity to lin-14. Cell 1993,
75:843-854.
8. Wightman B, Ha I, Ruvkun G: Posttranscriptional regulation of the
heterochronic gene lin-14 by lin-4 mediates temporal pattern formation
in C. elegans. Cell 1993, 75:855-862.
9. Vandenboom Ii TG, Li Y, Philip PA, Sarkar FH: MicroRNA and Cancer: Tiny
molecules with major implications. Curr Genomics 2008, 9:97-109.
10. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE,
et al: The 21-nucleotide let-7 RNA regulates developmental timing in
Caenorhabditis elegans. Nature 2000, 403:901-906.
11. Griffiths-Jones S, Grocock RJ, Van DS, Bateman A, Enright AJ: miRBase:
microRNA sequences, targets and gene nomenclature. Nucleic Acids Res
2006, 34:D140-D144.
12. Ambros V: MicroRNA pathways in flies and worms: growth, death, fat,
stress, and timing. Cell 2003, 113:673-676.
13. Coppola V, De MR, Bonci D: MicroRNAs and prostate cancer. Endocr Relat
Cancer 2010, 17:F1-F17.
14. Bushati N, Cohen SM: microRNA functions. Annu Rev Cell Dev Biol 2007,
23:175-205.
15. Stefani G, Slack FJ: Small non-coding RNAs in animal development. Nat
Rev Mol Cell Biol 2008, 9:219-230.
16. Gangaraju VK, Lin H: MicroRNAs: key regulators of stem cells. Nat Rev Mol
Cell Biol 2009, 10:116-125.
17. Baltimore D, Boldin MP, O’Connell RM, Rao DS, Taganov KD: MicroRNAs:
new regulators of immune cell development and function. Nat Immunol
2008, 9:839-845.
18. Cullen BR: Viral and cellular messenger RNA targets of viral microRNAs.
Nature 2009, 457:421-425.
19. Latronico MV, Condorelli G: MicroRNAs and cardiac pathology. Nat Rev
Cardiol 2009, 6:419-429.
20. Bushati N, Cohen SM: MicroRNAs in neurodegeneration. Curr Opin
Neurobiol 2008, 18:292-296.
21. Kloosterman WP, Plasterk RH: The diverse functions of microRNAs in
animal development and disease. Dev Cell 2006, 11:441-450.
22. Baranwal S, Alahari SK: miRNA control of tumor cell invasion and
metastasis. Int J Cancer 2010, 126:1283-1290.
23. Pang Y, Young CY, Yuan H: MicroRNAs and prostate cancer. Acta Biochim
Biophys Sin (Shanghai) 2010, 42:363-369.
24. Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, Dickinson S, et al: Role
for DNA methylation in the regulation of miR-200c and miR-141
expression in normal and cancer cells. PLoS One 2010, 5:e8697.
25. Aqeilan RI, Calin GA, Croce CM: miR-15a and miR-16-1 in cancer:
discovery, function and future perspectives. Cell Death Differ 2010,
17:215-220.
26. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, et al: An androgen-regulated
miRNA suppresses Bak1 expression and induces androgen-independent
growth of prostate cancer cells. Proc Natl Acad Sci USA 2007,
104:19983-19988.
27. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, et al:
MicroRNA-21 promotes cell transformation by targeting the
programmed cell death 4 gene. Oncogene 2008, 27:4373-4379.
28. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, et al:
Optimized high-throughput microRNA expression profiling provides
novel biomarker assessment of clinical prostate and breast cancer
biopsies. Mol Cancer 2006, 5:24.
29. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T:
MicroRNA expression profiling in prostate cancer. Cancer Res 2007,
67:6130-6135.
30. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al: MicroRNA genes are
transcribed by RNA polymerase II. EMBO J 2004, 23:4051-4060.
31. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ: Processing of
primary microRNAs by the Microprocessor complex. Nature 2004,
432:231-235.
32. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al: The nuclear RNase III
Drosha initiates microRNA processing. Nature 2003, 425:415-419.
33. Bohnsack MT, Czaplinski K, Gorlich D: Exportin 5 is a RanGTP-dependent
dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA
2004, 10:185-191.
34. Yi R, Qin Y, Macara IG, Cullen BR: Exportin-5 mediates the nuclear export
of pre-microRNAs and short hairpin RNAs. Genes Dev 2003, 17:3011-3016.
35. Bernstein E, Caudy AA, Hammond SM, Hannon GJ: Role for a bidentate
ribonuclease in the initiation step of RNA interference. Nature 2001,
409:363-366.
36. Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH: Dicer
functions in RNA interference and in synthesis of small RNA involved in
developmental timing in C. elegans. Genes Dev 2001, 15:2654-2659.
37. Hammond SM, Bernstein E, Beach D, Hannon GJ: An RNA-directed
nuclease mediates post-transcriptional gene silencing in Drosophila
cells. Nature 2000, 404:293-296.
Hassan et al. Journal of Hematology & Oncology 2012, 5:9
http://www.jhoonline.org/content/5/1/9
Page 8 of 1038. Schwarz DS, Hutvagner G, Haley B, Zamore PD: Evidence that siRNAs
function as guides, not primers, in the Drosophila and human RNAi
pathways. Mol Cell 2002, 10:537-548.
39. Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours:
accumulating evidence and unresolved questions. Nat Rev Cancer 2008,
8:755-768.
40. DeSano JT, Xu L: MicroRNA regulation of cancer stem cells and
therapeutic implications. AAPS J 2009, 11:682-692.
41. Papagiannakopoulos T, Kosik KS: MicroRNAs: regulators of oncogenesis
and stemness. BMC Med 2008, 6:15.
42. Dick JE: Normal and leukemic human stem cells assayed in SCID mice.
Semin Immunol 1996, 8:197-206.
43. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE: Targeting of CD44
eradicates human acute myeloid leukemic stem cells. Nat Med 2006,
12:1167-1174.
44. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ: Prospective
identification of tumorigenic prostate cancer stem cells. Cancer Res 2005,
65:10946-10951.
45. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, et al:
Highly purified CD44+ prostate cancer cells from xenograft human
tumors are enriched in tumorigenic and metastatic progenitor cells.
Oncogene 2006, 25:1696-1708.
46. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG: Hierarchical
organization of prostate cancer cells in xenograft tumors: the CD44
+alpha2beta1+ cell population is enriched in tumor-initiating cells.
Cancer Res 2007, 67:6796-6805.
47. Croce CM, Calin GA: miRNAs, cancer, and stem cell division. Cell 2005,
122:6-7.
48. Melton C, Judson RL, Blelloch R: Opposing microRNA families regulate
self-renewal in mouse embryonic stem cells. Nature 2010, 463:621-626.
49. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al: let-7 regulates self
renewal and tumorigenicity of breast cancer cells. Cell 2007,
131:1109-1123.
50. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al:
Downregulation of miRNA-200c links breast cancer stem cells with
normal stem cells. Cell 2009, 138:592-603.
51. Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, et al: Human embryonic
stem cells express a unique set of microRNAs. Dev Biol 2004, 270:488-498.
52. He L, He X, Lim LP, De SE, Xuan Z, Liang Y, et al: A microRNA component
of the p53 tumour suppressor network. Nature 2007, 447:1130-1134.
53. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N,
et al: Transcriptional activation of miR-34a contributes to p53-mediated
apoptosis. Mol Cell 2007, 26:731-743.
54. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH,
et al: Transactivation of miR-34a by p53 broadly influences gene
expression and promotes apoptosis. Mol Cell 2007, 26:745-752.
55. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al: p53-
mediated activation of miRNA34 candidate tumor-suppressor genes.
Curr Biol 2007, 17:1298-1307.
56. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, et al:
Differential regulation of microRNAs by p53 revealed by massively
parallel sequencing: miR-34a is a p53 target that induces apoptosis and
G1-arrest. Cell Cycle 2007, 6:1586-1593.
57. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al: The microRNA
miR-34a inhibits prostate cancer stem cells and metastasis by directly
repressing CD44. Nat Med 2011, 17:211-215.
58. Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal
transitions in development and disease. Cell 2009, 139:871-890.
59. Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, et al:
TMPRSS2/ERG promotes epithelial to mesenchymal transition through
the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One 2011, 6:
e21650.
60. Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J
Clin Invest 2009, 119:1420-1428.
61. Bracken CP, Gregory PA, Khew-Goodall Y, Goodall GJ: The role of
microRNAs in metastasis and epithelial-mesenchymal transition. Cell Mol
Life Sci 2009, 66:1682-1699.
62. Zeisberg M, Neilson EG: Biomarkers for epithelial-mesenchymal
transitions. J Clin Invest 2009, 119:1429-1437.
63. Ahmad A, Ali AS, Ali S, Wang Z, Kong D, Sarkar FH: MicroRNAs: Targets of
Interest in Breast Cancer Research. In MicroRNA: Expression, Detection and
Therapeutic Strategies. Edited by: Mulligan JA. New York: Nova Publishers;
2011:59-78.
64. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al:
Diagnostic and prognostic implications of microRNA profiling in prostate
carcinoma. Int J Cancer 2010, 126:1166-1176.
65. Ozen M, Creighton CJ, Ozdemir M, Ittmann M: Widespread deregulation of
microRNA expression in human prostate cancer. Oncogene 2008,
27:1788-1793.
66. Fu X, Xue C, Huang Y, Xie Y, Li Y: The activity and expression of
microRNAs in prostate cancers. Mol Biosyst 2010, 6:2561-2572.
67. Clape C, Fritz V, Henriquet C, Apparailly F, Fernandez PL, Iborra F, et al: miR-
143 interferes with ERK5 signaling, and abrogates prostate cancer
progression in mice. PLoS One 2009, 4:e7542.
68. Micalizzi DS, Farabaugh SM, Ford HL: Epithelial-mesenchymal transition in
cancer: parallels between normal development and tumor progression. J
Mammary Gland Biol Neoplasia 2010, 15:117-134.
69. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR, et al: miR-200
regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion,
and invasion of prostate cancer cells. Stem Cells 2009, 27:1712-1721.
70. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S, et al: Epithelial to
mesenchymal transition is mechanistically linked with stem cell
signatures in prostate cancer cells. PLoS One 2010, 5:e12445.
71. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, et al:
Circulating miRNAs are correlated with tumor progression in prostate
cancer. Int J Cancer 2011, 128:608-616.
72. Musumeci M, Coppola V, Addario A, Patrizii M, Maugeri-Sacca M, Memeo L,
et al: Control of tumor and microenvironment cross-talk by miR-15a and
miR-16 in prostate cancer. Oncogene 2011, 30:4231-4242.
73. Friedman RC, Farh KK, Burge CB, Bartel DP: Most mammalian mRNAs are
conserved targets of microRNAs. Genome Res 2009, 19:92-105.
74. Ahmad A, Aboukameel A, Kong D, Wang Z, Sethi S, Chen W, et al:
Phosphoglucose isomerase/autocrine motility factor mediates epithelial-
mesenchymal transition regulated by miR-200 in breast cancer cells.
Cancer Res 2011, 71:3400-3409.
75. Sikand K, Slaibi JE, Singh R, Slane SD, Shukla GC: miR 488* inhibits
androgen receptor expression in prostate carcinoma cells. Int J Cancer
2010, DOI: 10.1002/ijc.25753.
76. Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P: The role of microRNA-
221 and microRNA-222 in androgen-independent prostate cancer cell
lines. Cancer Res 2009, 69:3356-3363.
77. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA, et al:
miR-221 and miR-222 expression affects the proliferation potential of
human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem
2007, 282:23716-23724.
78. Zheng C, Yinghao S, Li J: MiR-221 expression affects invasion potential of
human prostate carcinoma cell lines by targeting DVL2. Med Oncol 2011,
DOI: 10.1007/s12032-011-9934-8.
79. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY: miR-21-mediated tumor growth.
Oncogene 2007, 26:2799-2803.
80. Selcuklu SD, Donoghue MT, Spillane C: miR-21 as a key regulator of
oncogenic processes. Biochem Soc Trans 2009, 37:918-925.
81. Li T, Li D, Sha J, Sun P, Huang Y: MicroRNA-21 directly targets MARCKS
and promotes apoptosis resistance and invasion in prostate cancer cells.
Biochem Biophys Res Commun 2009, 383:280-285.
82. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, et al:
miR-21: an androgen receptor-regulated microRNA that promotes
hormone-dependent and hormone-independent prostate cancer
growth. Cancer Res 2009, 69:7165-7169.
83. Bao B, Ali S, Kong D, Sarkar SH, Wang Z, Banerjee S, et al: Anti-tumor
activity of a novel compound-CDF is mediated by regulating miR-21,
miR-200, and PTEN in pancreatic cancer. PLoS One 2011, 6:e17850.
84. Lee YS, Kim HK, Chung S, Kim KS, Dutta A: Depletion of human micro-RNA
miR-125b reveals that it is critical for the proliferation of differentiated
cells but not for the down-regulation of putative targets during
differentiation. J Biol Chem 2005, 280:16635-16641.
85. Vere White RW, Vinall RL, Tepper CG, Shi XB: MicroRNAs and their
potential for translation in prostate cancer. Urol Oncol 2009, 27:307-311.
86. Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, et al:
Gemcitabine sensitivity can be induced in pancreatic cancer cells
through modulation of miR-200 and miR-21 expression by curcumin or
its analogue CDF. Cancer Res 2010, 70:3606-3617.
Hassan et al. Journal of Hematology & Oncology 2012, 5:9
http://www.jhoonline.org/content/5/1/9
Page 9 of 1087. Ali S, Almhanna K, Chen W, Philip PA, Sarkar FH: Differentially expressed
miRNAs in the plasma may provide a molecular signature for aggressive
pancreatic cancer. Am J Transl Res 2010, 3:28-47.
88. Ali S, Banerjee S, Logna F, Bao B, Philip PA, Korc M, et al: Inactivation of
Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic
mouse model of pancreatic cancer. J Cell Physiol 2011, DOI:10.1002/
jcp.24036.
89. Ali S, Ahmad A, Aboukameel A, Bao B, Padhye S, Philip PA, et al: Increased
Ras GTPase activity is regulated by miRNAs that can be attenuated by
CDF treatment in pancreatic cancer cells. Cancer Lett 2012, DOI:10.1016/j.
canlet.2012.01.013.
90. Yu Y, Kanwar SS, Patel BB, Oh PS, Nautiyal J, Sarkar FH, et al: MicroRNA-21
induces stemness by downregulating transforming growth factor beta
receptor 2 (TGFbetaR2) in colon cancer cells. Carcinogenesis 2012,
33:68-76.
doi:10.1186/1756-8722-5-9
Cite this article as: Hassan et al.: Recent updates on the role of
microRNAs in prostate cancer. Journal of Hematology & Oncology 2012
5:9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hassan et al. Journal of Hematology & Oncology 2012, 5:9
http://www.jhoonline.org/content/5/1/9
Page 10 of 10